News & Events

AFTD Webinar: FTD and ALS — A Collaborative Approach to Diagnosis and Care

We know of several genes that can cause hereditary FTD, ALS, and ALS with FTD, with C9orf72 the most common. Yet genetics is not the complete story, as these conditions…

MORE

Advancing Hope: AFTD-ADDF Partnership Announces New Award in Drug Discovery Program

AFTD has partnered with the Alzheimer’s Drug Discovery Foundation (ADDF) since 2007 to support preclinical research on promising new drugs through the Accelerating Drug Discovery for FTD program. We are…

MORE

Viewpoints of FTD – Brain Donation

While there is currently no cure or approved treatments for FTD, increasing numbers of diagnostic tools and experimental treatments are entering the clinical trial phase of their development. A major…

MORE

AFTD Volunteer Receives “Visionary of the Year 2024” Award for 40 Years of Advocacy

AFTD volunteer Wanda Smith received Alzheimer’s San Diego’s Visionary of the Year 2024 award for her FTD advocacy and awareness-raising efforts, which date back to the 1980s. Smith’s journey began…

MORE

AFTD Volunteer Speaks about Trading Career for New “Vocation” as Caregiver

Alma Valencia, an AFTD volunteer in California, shared the challenges, stresses, and “moments of joy” she experiences as her mother’s caregiver in an as-told-to essay published recently in Business Insider.…

MORE

Transposon Therapeutics Receives Fast Track Designation for PSP Treatment

Biotechnology company Transposon Therapeutics announced on May 21 that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for an intervention developed to treat progressive…

MORE

Biomarkers Consortium Letter of Intent to Qualify FTD Biomarker accepted by FDA

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced in May that the US Food and Drug Administration (FDA) has accepted its letter of intent to apply…

MORE

Aprinoia Therapeutics Receives Fast Track Designation for PET Tracer for PSP Diagnosis

Biopharmaceutical company Aprionoia Therapeutics announced that it has received an FDA Fast Track Designation for an imaging tracer used to diagnose progressive supranuclear palsy (PSP), an FTD disorder that primarily…

MORE